The GOLD ReGISTry: A Global, Prospective, Observational Registry Collecting Longitudinal Data on Patients with Advanced and Localised Gastrointestinal Stromal Tumours

摘要: Abstract Background Gastrointestinal stromal tumours (GISTs) are the most common gastrointestinal sarcomas. This global, prospective registry followed patients with advanced or localised GIST (2007–2011). Methods Current and evolving diagnostics, treatments outcome measures in were assessed. Eligible diagnosed within 15months of entry. No treatment plan was prescribed, no visit schedule mandated. Treating physicians recorded patient information, including tumour response, diagnostic methods, medications, surgeries performed, mutation status adverse events leading to dose/medication changes. Survival outcomes estimated using Kaplan–Meier method. Other data analysed descriptive statistics. Results The included 1663 (advanced GIST, n =1095; =537). Medications (e.g. tyrosine kinase inhibitor use dosing), disease progression recurrence physician assessment response consistent controlled trials prevailing clinical recommendations. In 30-month progression-free survival (PFS) (59.8%) overall (OS) (82.7%) higher than results from previously reported (≈40% ≈70%, respectively). Consistent guidelines, initial imatinib for complete surgical resection GIST. Computed tomography scans imaging technique used at diagnosis follow-up. Mutation analysis performed only 15.3% 14.5% respectively. Conclusions this real-world registry, treated received resection, accordance